Navigation Links
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
Date:12/3/2008

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today announced that data related to the Company's series of novel compounds that inhibit spleen tyrosine kinase (Syk) and its novel universal Factor Xa inhibitor antidote will be presented at the annual meeting of the American Society of Hematology (ASH) at the Moscone Center in San Francisco during December 6-9, 2008.

Portola's Syk inhibitor program is focused on developing specific oral inhibitors of this key signaling pathway, which modulate inflammation, certain cancers and thrombosis. The Company plans to study its compounds initially in rheumatoid arthritis and non-Hodgkin's Lymphoma and eventually intends to explore their potential in other inflammatory diseases and cancers. Portola is developing its universal Factor Xa inhibitor antidote to neutralize the effect of small molecule Factor Xa inhibitors in patients experiencing major bleeding and for patients undergoing emergent or elective surgery.

Details of the ASH presentations are below and full abstracts can be viewed on the ASH website at http://www.hematology.org.

Syk Inhibitor Program

"Specific Inhibition of Syk is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin's Lymphoma Cell Lines without Concomitant Inhibition of JAK" (abstract # 1794)

Saturday, December 6, 5:30 PM

Hall A (Moscone Center)

"PRT060318, a Novel Syk Inhibitor, Prevents Heparin-Induced Thrombocytopenia in a Transgenic Mouse Model" (abstract # 269)

Monday, December 8, 7:00 AM

3007-3009-3011 - West (Moscone Center)

"Specific Pharmacological Targeting of the Syk Kinase Activity in Platelets: A Nove
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
3. Novel Technology Breaks Through Cancer Pain
4. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
5. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. NIST team develops novel method for nanostructured polymer thin films
9. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... CA (PRWEB) June 18, 2013 (PRWEB) June 18, ... #1 time and attendance system in North America, ... that shares employee data and payroll records between ... AccountLinx Plus automates ExakTime software setup and ... software imports employee data from a business’ current ...
(Date:6/18/2013)... Phoenix, AZ (PRWEB) June 18, 2013 ... the 2013 Innovation Challenge Winner out of hundreds of ... in its spring Arizona Innovation Challenge . The ... the country for a technology commercialization challenge, granting a ... world’s most promising technology ventures. Nasseo’s state of the ...
(Date:6/18/2013)...  AMRI (NASDAQ: AMRI ) announced ... , site has received approval to expand its ... handle Schedule 2 and 2N controlled substances. The ... Burlington,s physical security and quality systems, ... http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With its ...
(Date:6/18/2013)... , June 18, 2013 ... has announced the addition of the report ... Companies " to their offering. ... briefly reviews basics of human genome variations, ... Current large and small sequencers are described ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... Cardium Therapeutics (NYSE Amex: CXM ) today ... the U.S. Food and Drug Administration (FDA) seeking marketing ... Excellagen XL is an advanced wound care management ... designed for use by physicians in patients with topical ...
... DUBLIN, Ireland, November 2 The Board of,Directors of ... Mr David,Stout joined the Board as a Non Executive Director ... Mr Stout has extensive pharmaceutical experience. Most recently he was,President, ... pharmaceutical operations in the United States, Europe,Japan and all other ...
... successful phase III trial points to the first new lupus ... 2 The Lupus Research Institute (LRI) and its National ... Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - ... the first successfully tested new drug developed specifically for people ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4New Shire Board Member 2Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus 2
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
(Date:6/17/2013)... The AGA Research Foundation and Horizon Pharma further ... gastroenterology with the 2013 AGA-Horizon Pharma Fellow Abstract Prizes ... "In its third year, this competition continues to grow ... promising careers in basic and clinical research," said Nicholas ... Foundation. "We are extremely proud of all that these ...
(Date:6/16/2013)... programs for female sex workers in India reduce rates ... a University of Toronto study has found. ... mostly in the southern states of Andhra Pradesh, Karnataka, ... Prabhat Jha from U of T,s Dalla Lana School ... Global Health Research (CGHR), examined the impact of prevention ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Horizon Pharma Abstract Prizes recognize promising fellows and students 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... and the environment will gather in Nairobi, Kenya this ... cycle of drought and food insecurity. The Beating Famine ... the Sahel region of Africa, this time through Niger, ... will take place on April 10-13 at the World ...
... 2012 The Canadian Journal of Cardiology ... Society,s atrial fibrillation guidelines. Atrial fibrillation is the ... stroke, illness in general, and death. It is, for example, ... year has seen important changes in the drugs available to ...
... known for its role in embryonic development and cancer ... or scleroderma, therapy. The finding, discovered by a cross-disciplinary ... Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg ... Arthritis & Rheumatism. "We showed, for ...
Cached Biology News:Beating famine: Sustainable food security through land regeneration in a changing climate 2New genetic path for scleroderma 2
... 3.1.21.1) is a nonspecific endonuclease that degrades ... by hydrolyzing phosphodiester linkages, producing mono and ... group. Ambion's RNase-free DNase I is of ... to degrade DNA in the presence of ...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... Perhaps sheer in-house demand is causing ... want your precious antibody. This can cause ... • Receive royalties for your hard ... and let us build it up and ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: